-
Ustekinumab dosing individualization in Crohn's disease guided by a population pharmacokinetic-pharmacodynamic model [Elektronski vir]Zdovc, Jurij, farmacija ...Ustekinumab is a monoclonal antibody used in Crohn's disease (CD). Dose optimization in case of non-response and the role of pharmacokinetic-pharmacodynamic (PK-PD) monitoring remain unresolved ... dilemmas in clinical practice. We aimed to develop a population PK-PD model for ustekinumab in CD and simulate efficacy of alternative dosing regimens. We included 57 patients and recorded their characteristics during 32 weeks after starting with ustekinumab therapy. Serum ustekinumab concentration was prospectively measured and fecal calprotectin (FC) concentration was used to monitor the disease activity. Ustekinumab PK-PD was described by a two-compartment target-mediated drug disposition model linked to an indirect response model. Lower fat-free mass, higher serum albumin, previous non-exposure to biologics, FCGR3A-158 V/V variant and lower C-reactive protein were associated with higher ustekinumab exposure. Model-based simulation suggested that 41.9% of patients receiving standard dosing achieve biochemical remission at week 32. In patients not achieving remission with standard dosing at week 16, transition to 4-weekly subcutaneous maintenance dosing with or without intravenous reinduction resulted in comparably higher remission rates at week 32 (51.1% vs. 49.2%, respectively). Our findings could be used to guide stratified ustekinumab treatment in CD, particularly in patients with unfavorable characteristics, who might benefit from early transition to 4-weekly maintenance dosing.Vir: Pharmaceutics [Elektronski vir]. - ISSN 1999-4923 (Vol. 13, iss. 10, 2021, str. 1-16)Vrsta gradiva - e-članek ; neleposlovje za odrasleLeto - 2021Jezik - angleškiCOBISS.SI-ID - 78625027
Avtor
Zdovc, Jurij, farmacija |
Hanžel, Jurij |
Kurent, Tina, dr. med. |
Sever, Nejc, dr. med. |
Koželj, Matic |
Smrekar, Nataša, 1967- |
Novak, Gregor, farmacevt |
Štabuc, Borut |
Vovk, Tomaž, 1972- |
Ostanek, Barbara, 1972- |
Drobne, David |
Grabnar, Iztok
Teme
Crohnova bolezen |
Tarčna zdravila |
vnetje črevesja |
terapevtsko spremljanje zdravil |
fekalni kalprotektin |
ustekinumab |
inflammatory bowel disease |
fecal calprotectin |
pharmacokinetics-pharmacodynamics |
therapeutic drug monitoring
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Zdovc, Jurij, farmacija | 51148 |
Hanžel, Jurij | 54194 |
Kurent, Tina, dr. med. | ![]() |
Sever, Nejc, dr. med. | ![]() |
Koželj, Matic | 38330 |
Smrekar, Nataša, 1967- | 17902 |
Novak, Gregor, farmacevt | ![]() |
Štabuc, Borut | 11949 |
Vovk, Tomaž, 1972- | 18155 |
Ostanek, Barbara, 1972- | 18154 |
Drobne, David | 38327 |
Grabnar, Iztok | 16107 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.